MwanzoDRREDDY • NSE
add
Dr Reddy's Laboratories Ltd
Bei iliyotangulia
₹ 1,195.35
Bei za siku
₹ 1,193.60 - ₹ 1,223.20
Bei za mwaka
₹ 1,074.00 - ₹ 1,421.49
Thamani ya kampuni katika soko
1.01T INR
Wastani wa hisa zilizouzwa
1.48M
Uwiano wa bei na mapato
18.96
Mgao wa faida
0.66%
Ubadilishanaji wa msingi
NSE
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(INR) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato | 80.16B | 16.51% |
Matumizi ya uendeshaji wa biashara | 29.72B | 24.54% |
Mapato halisi | 12.55B | -15.18% |
Kiwango cha faida halisi | 15.66 | -27.20% |
Mapato kwa kila hisa | 15.83 | -11.13% |
EBITDA | 22.02B | 8.53% |
Asilimia ya kodi ya mapato | 30.01% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
(INR) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 63.07B | -7.15% |
Jumla ya mali | 465.96B | 34.27% |
Jumla ya dhima | 156.67B | 66.79% |
Jumla ya hisa | 309.28B | — |
hisa zilizosalia | 833.05M | — |
Uwiano wa bei na thamani | 3.26 | — |
Faida inayotokana na mali | 10.24% | — |
Faida inayotokana mtaji | 13.21% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
(INR) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato halisi | 12.55B | -15.18% |
Pesa kutokana na shughuli | 9.32B | -48.03% |
Pesa kutokana na uwekezaji | -19.07B | -322.21% |
Pesa kutokana na ufadhili | 16.15B | 329.53% |
Mabadiliko halisi ya pesa taslimu | 6.37B | 1.03% |
Mtiririko huru wa pesa | 3.92B | -72.47% |
Kuhusu
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1984
Makao Makuu
Tovuti
Wafanyakazi
27,048